You are here:

rivaroxaban (Xarelto) DVT


following a full submission:
rivaroxaban (Xarelto®) is accepted for use within NHS Scotland.
Indication under review: treatment of deep vein thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults.
Rivaroxaban has been shown to be non-inferior to standard anticoagulant therapy including a low molecular weight heparin in combination with a vitamin K antagonist for the treatment of proximal DVT and prevention of recurrence.
Experience with rivaroxaban in this indication for more than 12 months is limited therefore the cost-effectiveness of indefinite treatment has not been demonstrated.

Drug Details

Drug Name: rivaroxaban (Xarelto) DVT
SMC Drug ID: 755/12
Manufacturer: Bayer plc/Bayer Schering Pharma
Indication: For the treatment of DVT and prevention of recurrent DVT & pulmonary embolism following acute DVT in adults
BNF Category:
Sub Category: 2.8 Anticoagulants and protamine
Submission Type: Full submission
Status: Accepted
Date Advice Published: 13 February 2012